Use of β-Blockers in Patients with COPD

Abstract

OBJECTIVE:

To evaluate the safety and cardiovascular benefits of β-blocker therapy in patients with chronic obstructive pulmonary disease (COPD).

DATA SOURCES:

Clinical literature was accessed through MEDLINE (1966–February 2003). Key search terms included chronic obstructive pulmonary disease and adrenergic β-antagonists.

DATA SYNTHESIS:

β-Blockers are often avoided in patients with COPD because of fear of bronchoconstriction, despite the known cardiovascular mortality benefits. A review of studies evaluating the use of β-blockers in COPD was undertaken.

CONCLUSIONS:

The literature supports the safety and mortality benefits of using β-blockers in COPD. Patients with mild to moderate COPD should receive cardioselective β-blocker therapy when a strong indication exists.